Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380423 | 0.84 | IRAK4 (0.51) | GSK3AIRAK4KDM4EL3MBTL1HTT | |
| SCHEMBL17303154 | 0.79 | HTT (0.55) | GSK3AIRAK4STING1RAB9AHTT | |
| SCHEMBL309036 | 0.78 | IRAK4 (0.58) | IRAK4KDM4ESTING1RAB9AHTT | |
| SCHEMBL1419803 | 0.76 | KDM4E (0.51) | IRAK4KDM4ETDP1STING1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL31474423 | 0.76 | IRAK4 (0.57) | IRAK4KDM4ESTING1RAB9AHTT | |
| Hydrochloric Acid SCHEMBL30152392 | 0.76 | IRAK4 (0.57) | IRAK4KDM4ESTING1RAB9AHTT | |
| SCHEMBL21331457 | 0.76 | ALDH1A1 (0.49) | KDM4ERAB9AMAPTALDH1A1TSHR | |
| SCHEMBL4283322 | 0.75 | HSD11B1 (0.41) | IRAK4KDM4ETDP1STING1RAB9A | |
| SCHEMBL1419899 | 0.74 | KDM4E (0.50) | KDM4ETDP1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL31278096 | 0.74 | GSK3A (0.45) | GSK3AKDM4ETDP1L3MBTL1KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276463-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3A 2/4885IRAK4 3327/4885KDM4E 2252/4885 |
| US-10774086-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3A 2/4885IRAK4 3327/4885KDM4E 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.